Raltitrexed–Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients
Camillo Porta(University of Pavia), Luciano Mutti(University of L'Aquila), Lucia Bonomi, Chiara Paglino, Ilaria Imarisio(University of Pavia), Andrea Sartore‐Bianchi(University of Milan), Matteo Zimatore
Cited by 51
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821